secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-02-22T23:59:59+00:00
Accession:  0001787306-22-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis reports Q4 2021 net loss of $71.3M, cash $388.6M; FDA accepted NDA for roflumilast cream
--------------------------------------------------------------------------------

- Net loss of $71.3M ($1.42 per share) for Q4 2021 vs $34.0M ($0.79) in Q4 2020.
- Cash, equivalents and marketable securities $388.6M as of Dec 31, 2021; runway extended into 2024.
- FDA accepted NDA for roflumilast cream in plaque psoriasis with PDUFA date July 29, 2022.
- Completed enrollment of Phase 3 trial for roflumilast foam in seborrheic dermatitis; topline data mid-2022.
- Secured $225M non-dilutive loan facility from SLR Capital Partners in December 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000008/0001787306-22-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000008/arqt-20220222.htm
  HTML page:      https://secwatch.observer/filing/0001787306-22-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer